

REPL::ANNUAL GENERAL MEETING::VOLUNTARY

Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Security

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Announcement Details

Announcement Title

Annual General Meeting

Date & Time of Broadcast

26-Apr-2019 18:30:04

Status

Replacement

Announcement Reference

SG190410MEET7WE3

Submitted By (Co./ Ind. Name)

Lim Sher Mei

Designation

Company Secretary

Financial Year End

31/12/2018

Event Narrative

Narrative Type	Narrative Text
Additional Text	Please see attached notice of Annual General Meeting.
Additional Text	Please see attached presentation slides and results of the Annual General Meeting held on 26 April 2019,

Event Dates

Meeting Date and Time

26/04/2019 10:00:00

Response Deadline Date

23/04/2019 10:00:00

Event Venue(s)

Place

Venue(s)	Venue details
Meeting Venue	16 Tai Seng Street #04-01 Singapore 534138

Attachments

[Hyphens-Notice%20of%20AGM.pdf](#)

[Hyphens%20AGM%20FY2018%20Presentation.pdf](#)

[HPIL%20-%20Annt%20-%20Results%20of%20AGM_260419.pdf](#)

Total size =3383K MB

Related Announcements

Related Announcements

[10/04/2019 18:13:48](#)

HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201735688C)

(Incorporated in the Republic of Singapore)

-
1. **RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 APRIL 2019**
 2. **RE-APPOINTMENT OF DIRECTORS**
-

1. RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 APRIL 2019

The Board of Directors of Hyphens Pharma International Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that all resolutions as set out in the Notice of Annual General Meeting dated 11 April 2019 were duly passed by the shareholders of the Company by way of poll at the Annual General Meeting (“**AGM**”) held on 26 April 2019.

The information as required under Rule 704(15) of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rule of Catalyst (“**Rules of Catalyst**”) is set out below:

(a) Poll Results

The results of the poll on each of the resolutions passed at the AGM are as follows:

Resolution Number and Details	Total No. of Shares Represented by Votes For and Against	For		Against	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
Ordinary Resolution 1 To receive and adopt the Directors’ Statement and the Audited Financial Statements of the Company for the financial year ended 31 December 2018 together with the Auditors’ Report thereon	209,417,040	209,417,040	100	0	0

HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201735688C)

(Incorporated in the Republic of Singapore)

Resolution Number and Details	Total No. of Shares Represented by Votes For and Against	For		Against	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
Ordinary Resolution 2 To declare a final tax exempt (one-tier) dividend of 0.55 cents per ordinary share for the financial year ended 31 December 2018	209,417,040	209,417,040	100	0	0
Ordinary Resolution 3 To re-elect Mr Lim See Wah as Director	209,417,040	209,417,040	100	0	0
Ordinary Resolution 4 To re-elect Mr Heng Wee Koon as Director	209,417,040	209,417,040	100	0	0
Ordinary Resolution 5 To re-elect Mr Ng Eng Leng as Director	209,417,040	209,417,040	100	0	0
Ordinary Resolution 6 To re-elect Dr Poon Thong Yuen as Director	209,417,040	209,417,040	100	0	0

HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201735688C)

(Incorporated in the Republic of Singapore)

Resolution Number and Details	Total No. of Shares Represented by Votes For and Against	For		Against	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
Ordinary Resolution 7 To approve the Directors' fees of SGD 167,000 for the financial year ended 31 December 2018	209,417,040	209,417,040	100	0	0
Ordinary Resolution 8 To re-appoint RSM Chio Lim LLP as auditors of the Company and authorise the Directors to fix their remuneration	209,382,040	209,382,040	100	0	0
Ordinary Resolution 9 Authority to allot and issue shares	209,382,040	198,501,240	94.80	10,880,800	5.20
Ordinary Resolution 10 Authority to grant awards and issue shares in accordance with Hyphens Share Plan	208,089,540	197,208,740	94.77	10,880,800	5.23

HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201735688C)

(Incorporated in the Republic of Singapore)

Resolution Number and Details	Total No. of Shares Represented by Votes For and Against	For		Against	
		Number of Shares	Percentage (%)	Number of Shares	Percentage (%)
Ordinary Resolution 11 Authority to grant options and issue shares in accordance with Hyphens Share Option Scheme.	208,075,340	197,197,540	94.77	10,877,800	5.23

(b) Abstention from Voting

Details of parties who have abstained from voting on the resolutions tabled at the AGM are set out below:

Resolution Number and Details	Name	Number of Shares Held
Ordinary Resolution 10 ⁽ⁱ⁾ Authority to grant awards and issue shares in accordance with Hyphens Share Plan	Employees and others who are eligible to participate in the Hyphens Share Plan	1,292,500
Ordinary Resolution 11 ⁽ⁱ⁾ Authority to grant options and issue shares in accordance with Hyphens Share Option Scheme.	Employees and others who are eligible to participate in the Hyphens Share Option Scheme	1,292,500

Note:

- (i) No party was required to abstain from voting on the resolutions put to the AGM. Nonetheless, as good corporate governance, all Directors and employees of the Group, who are also shareholders and are eligible to participate in the Hyphens Share Plan and the Hyphens Share Option Scheme, including proxies of such shareholders, are requested to abstain from voting at the AGM in respect of Ordinary Resolutions 10 and 11.

HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201735688C)

(Incorporated in the Republic of Singapore)

(c) Scrutineer

Drewcorp Services Pte Ltd was appointed as the Company's scrutineer for the AGM.

2. RE-APPOINTMENT OF DIRECTORS – STATEMENT PURSUANT TO RULE 704(7) OF THE RULES OF CATALIST

- (a) Mr Lim See Wah was re-elected as a Director of the Company, he shall remain as the Executive Chairman and Chief Executive Officer of the Company.
- (b) Mr Heng Wee Koon was re-elected as a Director of the Company, he shall remain as the Lead Independent Director, the Chairman of the Audit Committee, a member of the Nominating Committee and a member of the Remuneration Committee and shall be considered independent for the purpose of Rule 704(7) of the Rules of Catalist.
- (c) Mr Ng Eng Leng was re-elected as a Director of the Company, he shall remain as the Chairman of the Remuneration Committee and a member of the Audit Committee and shall be considered independent for the purpose of Rule 704(7) of the Rules of Catalist.
- (d) Dr Poon Thong Yuen was re-elected as a Director of the Company, he shall remain as the Chairman of the Nominating Committee, a member of the Audit Committee and a member of the Remuneration Committee and shall be considered independent for the purpose of Rule 704(7) of the Rules of Catalist.

BY ORDER OF THE BOARD

Lim See Wah
Executive Chairman and Chief Executive Officer
Date: 26 April 2019

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("Sponsor") for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this announcement.


This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any information, statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President, who can be contacted at 12 Marina Boulevard Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone +65 6878 8888.



Hyphens Pharma International Limited

Annual General Meeting
26 April 2019



HYPHENS PHARMA INTL LTD (SGX: 1J5)

DISCLAIMER

This presentation has been prepared by Hyphens Pharma International Limited (the "**Company**" and, together with its subsidiaries, the "**Group**").

This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated, photographed or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated or quoted, directly or indirectly, to any person either in your organisation or elsewhere.

None of the Company, DBS Bank Ltd. (the "**Sponsor**") nor any of their respective affiliates, advisors and representatives makes any representation regarding, or assumes any responsibility or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of the content in this presentation.

By attending or viewing all or part of this presentation, you:

- i. represent and warrant that you are lawfully able to receive this presentation under the laws of the jurisdiction in which you are located and all other applicable laws;
- ii. agree to be bound by the limitations and restrictions described herein; and
- iii. agree to maintain confidentiality regarding the information disclosed in this presentation and to continue to adhere to all applicable securities and insider trading rules and laws in any jurisdiction at all times.

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information in this presentation is a summary only and does not purport to contain all of the information that may be required to evaluate the Company or any potential transaction. Any potential transaction could be made available to you in accordance with applicable laws and regulations, including the distribution of any required documents for such potential transaction and such documents will supersede all prior information provided to you, herein or otherwise. Information in this presentation is qualified in its entirety by reference to an offering document for any potential transaction, if it proceeds.

None of the Company, the Sponsor, and any of their respective holding companies, subsidiaries, associated undertakings, controlling persons, affiliates, and any of their respective directors, officers, partners, employees, agents, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. It is not the intention to provide, and you may not rely on the content of this presentation as providing, a complete or comprehensive analysis of the Company's or the Group's financial or trading position or prospects. The information and opinions contained in this presentation is provided as at the date hereof (unless otherwise indicated) and are subject to change without notice. This presentation may not contain all material information concerning the Company or the Group.

The information contained in this presentation has not been independently verified. The accuracy and completeness of the information and opinions in this presentation is not guaranteed and no representation or warranty, expressed or implied, is made as to, and no reliance, in whole or in part, should be placed on the fairness, accuracy, completeness or correctness of the information, opinions or assumptions contained herein. Further, nothing in this presentation should be construed as constituting legal, business, tax or financial advice. None of the Sponsor and its subsidiaries or affiliates has independently verified, approved or endorsed the material herein.

The information in this presentation includes historical information about and relevant to the Group that should not be regarded as an indication of the future performance of the Group or the value of the shares of the Company. This presentation also contains forward-looking statements that may be identified by their use of words like "plans", "expects", "will", "anticipates", "believes", "intends", "depends", "projects", "estimates" or other words of similar meaning and that involve assumptions, risks and uncertainties. All statements that address expectations or projections about the future and all statements other than statements of historical facts included in this presentation, including, but not limited to, statements about the strategy for growth, product development, market position, expenditures, and financial results, are forward-looking statements. Such forward-looking statements are based on certain assumptions and expectations of future events regarding the Group's present and future business strategies and the environment in which the Group will operate, and must be read together with those assumptions. No assurance or guarantee is given that these assumptions and expectations are accurate or will be realised. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. These risks, uncertainties and assumptions include, without limitation, general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other entities, shifts in customer demand, customers and partners, changes in operating expenses including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of the Group. Past performance is not necessarily indicative of future performance. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the Company's current view of future events. None of the Company and the Sponsor, their respective affiliates and their respective agents assumes any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.

This presentation has not been and will not be registered as a prospectus with the Monetary Authority of Singapore under the Securities and Futures Act, Chapter 289 of Singapore and accordingly, this document may not be distributed, either directly or indirectly, to the public or any member of the public in Singapore. Failure to comply with this directive may violate applicable laws. This presentation was prepared exclusively for the parties presently being invited for the purposes of discussion. It is directed only at persons who are lawfully able to receive this presentation under the laws of the jurisdictions in which they are located and all other applicable laws ("**relevant persons**"). This presentation must not be acted on or relied on by persons who are not relevant persons.

Neither this presentation nor any of its content may be used without the prior written consent of the Company and the Sponsor. Any forwarding, distribution or reproduction of the information in this presentation electronically or otherwise, in whole or in part, is unauthorised.



COMPANY SNAPSHOT



**ON
18 MAY
2018**

**LISTED ON
THE
SGX-CATALIST**

2018 REVENUE

\$S121 MILLION



5 COUNTRIES

450 PERSONNEL



14 of our products are
sold *every minute!*



**3 CORE
BUSINESSES**



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



OUR **BUSINESS** SEGMENTS

**Specialty Pharma
Principals**

1

**Proprietary
Brands**


2

**Medical
Hypermart and
Digital**

3



SPECIALTY PHARMA PRINCIPALS



What We Do

1. Handle specialised products, under exclusive agreements with our principals from Europe and the US.
2. Register and hold product licenses with local authorities.
3. Promote products through medical representatives to specialists and GPs.





OUR REGIONAL FOOTPRINT



CONTRAST MEDIA PRODUCTS

GUERBET – XENETIX® • DOTAREM® • LIPIODOL®



Our products
are used for:

- X-Rays
- CT Scans
- MRI

Participation in
Scientific Congresses

25 years of
working
relationship

2018 Revenue
Contribution: **13.7%**



Booth Presence



Symposiums



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



ENT (EAR, NOSE, THROAT) & ALLERGY



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



OTHER SPECIALTY PHARMA PRODUCTS

Interventional Cardiology
(Biosensors Coronary Stents)

Gastroenterology

Otorhinolaryngology

Obstetrics & Gynaecology

Rheumatology

Ophthalmology

Neuroscience & Psychiatry


Family Medicine



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



PROPRIETARY BRANDS



What We Do

1. Direct ownership of the products under various brand names and market them to the world.
2. Constantly engaged in product research & development.
3. Contract manufacture these products, bearing our trademarks.



BRANDS WE OWN



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



Ceradan® ATOPIC DERMATITIS RANGE



*IQVIA 2018 Q3 Survey on Top-of-Mind Awareness on 31 Private Dermatologists in Singapore



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



TDF® DERMA FORMULA

HOME CARE



OILY & ACNE

DRY &
SENSITIVE

HYPER-
PIGMENTATION

AGE DEFENSE



CHEMICAL PEEL





A WELL-REGARDED BRAND BY CONSUMERS

- ✓ **Brand that I can trust[#]**
- ✓ **Good value for money[#]**



SINGAPORE'S NO. 1* OMEGA-3



[#] 2018 Nielsen Survey – A Comprehensive and Holistic Understanding of the Health Supplement Market
^{*} Best selling fish oil (Omega-3) supplement awarded by Guardian, Unity & Watsons (since 2013)



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group






NUTRITIONAL SUPPLEMENTS



Clinical Series is a professional range of health supplement products to meet the **clinical nutrition needs** of patients



WE MARKET OUR BRANDS IN



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



MEDICAL HYPERMART AND DIGITAL



What We Do

1. Wholesaler of pharmaceutical products and medical supplies.
2. Cater largely to private clinics and pharmacies.
3. > 3,000 customers and > 4,000 items in our inventory.
4. Have B2B e-commerce platform that facilitates 24/7 ordering.
5. Only in Singapore at the moment.



MEDICAL HYPERMART AND DIGITAL



Over 1,500
members
on Medical
Hypermart
!



1st pharmaceutical wholesaler in Singapore
to establish an online platform and capture
new digital opportunities



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



FINANCIAL SNAPSHOT AS AT 31 DEC 2018

FY2018

REVENUE

S\$120.9m

PROFIT

S\$5.4m

(after IPO expense of S\$0.9m)

S\$7.5m

cash inflow from
operating activities

S\$22.4m

cash and cash
equivalent



7.7%

gearing
ratio¹

¹ Total Debt / Total Equity

0.55c

dividend per share



**Strong Cash
Generative Business**



Low Gearing Ratio

>30%


dividend payout

At Least **30%** of Net Profits Attributable to Shareholders in FY2018
and FY2019 Intended to be Distributed as Dividends




FINANCIAL HIGHLIGHTS

Revenue (S\$m)




Profit After Tax (S\$m)




REVENUE SEGMENT BREAKDOWN BY BUSINESS & GEOGRAPHY

**FY18 Revenue Breakdown by
Business (S\$m)**



**FY18 Revenue Breakdown by
Geography (S\$m)**



FUTURE GROWTH

- **New product launches**
 - Products with patented and patent pending technologies to grow the skin health business
 - Continue to enhance product offerings through licencing and research collaborations
 - Launching new specialty pharma products in regional markets
- **Establishing a broader geographical footprint**
 - Cementing leadership position in Singapore and deepening ASEAN presence
 - Marketing development in countries already operating in
 - Expanding international footprint
- **Digital technologies**
 - Exploring potential opportunities within this segment
- **Driven by enhanced human capital**
 - Investing in manpower to support expansion plans
 - Associate Marketing Director
 - Business Director, Dermatology
 - Vice President, Philippines
 - Business Development Director





Hyphens Pharma International Limited (SGX: 1J5)
 16 Tai Seng Street, Level 4, Singapore 534138
www.hyphens.com.sg

